- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07472049
Actividad Sintomática y Sistémica de la Placa Aterosclerótica en Pacientes con Enfermedad Arterial Periférica Mediante Imágenes Innovadoras (SISYPHUS)
The goal of this observational study is to characterise the relationships between inflammation, microcalcification and thrombus activity in atherosclerotic plaques in peripheral and systemic vascular territories in patients with symptomatic peripheral arterial disease.
Descripción general del estudio
Estado
Descripción detallada
In peripheral arterial disease (PAD), arteries in the lower body can become narrowed and develop blockages due to a process called atherosclerosis, leading to reduced blood flow to the lower limbs. Symptoms can range from mild cramping pain in legs on walking, to loss of parts of the leg. Patients with PAD are also at a high risk of blockages in other arteries in the body that can lead to problems such as heart attacks and strokes. Despite improvements in medical treatments and surgery, the outlook for patients with PAD has not improved.
Further information is required to understand the relationships between the processes that lead to narrowing and blockages (atherosclerosis) of the arteries and if they behave the same in different parts of the body. This can help to identify targeted treatments to reduce the risk of the disease getting worse and avoid heart attacks and strokes.
In this study investigators plan to recruit 100 people with symptomatic PAD to undergo a series of whole body PET-CT and CT angiogram scans using different tracers targeting the processes involved in atherosclerosis. Investigators will aim to co-enrol patients taking part in the LEADER-PAD study (NCT04774159).
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Allison c Winarski, MBChB, MRCS(Ed)
- Número de teléfono: +447495905258
- Correo electrónico: awinarsk@ed.ac.uk
Copia de seguridad de contactos de estudio
- Nombre: Rachael O Forsythe, MBChB, PhD, FRCS (Vascular)
- Número de teléfono: +44 01312423585
- Correo electrónico: rachael.forsythe@ed.ac.uk
Ubicaciones de estudio
-
-
Midlothian
-
Edinburgh, Midlothian, Reino Unido, EH16 4SA
- Reclutamiento
- Royal Infirmary of Edinburgh
-
Contacto:
- Allison C Winarski, MBChB MRSC(Ed)
- Número de teléfono: +447495905258
- Correo electrónico: awinarsk@ed.ac.uk
-
Contacto:
- Rachael O Forsythe, MBChB, PhD, FRCS (Vascular)
- Número de teléfono: 01312423585
- Correo electrónico: rachael.forsythe@ed.ac.uk
-
Sub-Investigador:
- Allison C Winarski, MBChB MRCS (Ed)
-
Investigador principal:
- Rachael O Forsythe, MBChB, PhD, FRCS (Vascular)
-
Sub-Investigador:
- David E Newby, BSc (Hons)PhD BM DM DSc FRCP
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients will be prosectively recruited from vascular outpatient clinics and inpatient wards.
Descripción
Inclusion Criteria:
-
Male or female aged > 18 years
-
Symptomatic atherosclerotic peripheral artery disease;
-
Intermittent claudication; with ankle/arm blood pressure ratio <0.90 or artery stenosis >50% in addition to at least one of the following;
- >1 vascular bed affected by atherosclerosis
- Diabetes
- Heart failure
- Chronic kidney disease (eGFR < 60 mL/min/1.73 m2)
-
Rest pain or necrosis of limb or gangrene of limb
-
Revascularization defined as limb bypass surgery or endovascular revascularization procedures (irrespective of the specific device used), including percutaneous transluminal angioplasty/stent of iliac or infra-inguinal arteries or extra-anatomical bypass surgery
-
Leg or foot amputation for arterial vascular indications
-
-
Ability to give written or verbal informed consent
Exclusion Criteria:
- Contraindication to colchicine or iodinated contrast
- Long term requirement for colchicine for another clinical indication
- Active diarrhoea
- Recent lower limb revascularisation for symptomatic disease (<6 weeks)
- Renal failure (glomerular filtration rate <30 mL/min/1.73 m2)
- Cirrhosis or severe chronic liver disease
- Women who are pregnant or breast-feeding
- Women of child-bearing potential not protected by reliable contraception or is planning conception during the study
- Current or planned long term use of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics (apart from azithromycin)
- Patients deemed unlikely to return for follow up
- Life expectancy <1 year
- Inability or unwilling to give informed consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Pacientes con enfermedad arterial periférica sintomática
|
Targeting vascular inflammation Targeting thrombus activity Targeting vascular microcalcification To determine anatomical and morphological atherosclerotic plaque characteristics |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Quantification of PET tracer uptake of [68Ga]DOTATATE, [18F]GP1 and [18F]NaF in the symptomatic lower limb(s)
Periodo de tiempo: From baseline imaging until completion imaging at 1 year
|
The 3 primary endpoints will be the location and degree of:
|
From baseline imaging until completion imaging at 1 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Quantification of PET tracer uptake of [68Ga]DOTATATE, [18F]GP1 and [18F]NaF in remote arterial territories
Periodo de tiempo: From baseline imaging until completion imaging at 1 year
|
The secondary outcome measures will be the location and degree of inflammation, calcification and thrombus activity in remote arterial territories, including the coronary arteries, cerebral arteries, aorta and mesenteric vessels, as determined by SUVs of [68Ga]DOTATATE, [18F]NaF and [18F]GP1, respectively. |
From baseline imaging until completion imaging at 1 year
|
|
CT plaque morphology
Periodo de tiempo: From baseline imaging to completion imaging at 1 year
|
Investigators will characterise CT plaque morphology (total, calcified, non-calcified and low-attenuation plaque) in peripheral and systemic arterial beds and compare this to areas of [68Ga]DOTATATE, [18F]GP1 and [18F]NaF uptake. |
From baseline imaging to completion imaging at 1 year
|
|
The association between patient risk factors for cardiovascular disease and PET tracer uptake
Periodo de tiempo: Frome baseline imaging to completion imaging at 1 year
|
Investigators will explore the association between patient risk factors for cardiovascular disease (hypertension, diabetes, smoking) and the degree of [68Ga]DOTATATE, [18F]GP1 and [18F]NaF uptake as quantified by standard uptake values (SUVs). This will be measured by odds ratio (OR) with 95% confidence interval (CI) for each risk factor-tracer combination. |
Frome baseline imaging to completion imaging at 1 year
|
|
The progression of microcalcification, as defined by [18F]NaF uptake, to macrocalcification.
Periodo de tiempo: From baseline imaging to completion imaging at 1 year
|
Investigators will also aim to characterise the relationship between microcalcification progressing to calcification and the uptake of [18F]NaF. This will be assessed using baseline and follow-up [18F]NaF PET-CT SUVs and their correlation with calcified regions on CT angiography. |
From baseline imaging to completion imaging at 1 year
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Major adverse cardiovascular events (MACE) and major adverse limb events (MALE)
Periodo de tiempo: From baseline imaging to completion imaging at 1 year
|
Exploratory endpoints will include major adverse cardiovascular events (acute myocardial infarction, stroke or cardiovascular death) and major adverse limb events (revascularisation or lower limb amputation) as well as death from any cause. |
From baseline imaging to completion imaging at 1 year
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Rachael O Forsythe, MBChB, PhD, FRCS (Vascular), University of Edinburgh
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Procesos Patológicos
- Enfermedad crónica
- Atributos de la enfermedad
- Aterosclerosis
- Arteriosclerosis
- Enfermedades arteriales oclusivas
- Enfermedades vasculares periféricas
- Isquemia
- Condiciones Patológicas, Signos y Síntomas
- Isquemia crónica que amenaza las extremidades
- Enfermedades cardiovasculares
- Enfermedad arterial periférica
Otros números de identificación del estudio
- AC25008
- BHF PG/24/12097 (Otro número de subvención/financiamiento: British Heart Foundation)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .